Your browser is no longer supported. Please, upgrade your browser.
Settings
PTCT PTC Therapeutics, Inc. daily Stock Chart
PTCT [NASD]
PTC Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.34 Insider Own0.20% Shs Outstand46.14M Perf Week-0.95%
Market Cap1.97B Forward P/E- EPS next Y-0.17 Insider Trans-21.43% Shs Float44.51M Perf Month22.01%
Income-15.20M PEG- EPS next Q-0.40 Inst Own84.20% Short Float6.95% Perf Quarter35.35%
Sales244.70M P/S8.05 EPS this Y79.90% Inst Trans-9.67% Short Ratio2.43 Perf Half Y74.17%
Book/sh5.80 P/B7.36 EPS next Y87.90% ROA-14.80% Target Price41.50 Perf Year136.90%
Cash/sh6.42 P/C6.65 EPS next 5Y-9.51% ROE-34.00% 52W Range14.56 - 52.95 Perf YTD155.94%
Dividend- P/FCF- EPS past 5Y- ROI-6.50% 52W High-19.98% Beta1.95
Dividend %- Quick Ratio4.20 Sales past 5Y41.80% Gross Margin96.10% 52W Low190.98% ATR2.10
Employees373 Current Ratio4.30 Sales Q/Q43.10% Oper. Margin-19.50% RSI (14)59.69 Volatility5.14% 5.61%
OptionableYes Debt/Eq0.56 EPS Q/Q53.20% Profit Margin-25.00% Rel Volume0.42 Prev Close42.69
ShortableYes LT Debt/Eq0.55 EarningsAug 07 AMC Payout- Avg Volume1.27M Price42.37
Recom2.40 SMA205.90% SMA5012.57% SMA20054.26% Volume106,208 Change-0.75%
Jul-19-18Initiated Credit Suisse Outperform $49
Jun-18-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Apr-04-18Downgrade Barclays Equal Weight → Underweight $24 → $26
Jan-29-18Resumed RBC Capital Mkts Sector Perform
Nov-16-17Upgrade JP Morgan Underweight → Neutral
Oct-26-17Downgrade BofA/Merrill Neutral → Underperform
Oct-09-17Downgrade JP Morgan Neutral → Underweight
Sep-29-17Reiterated RBC Capital Mkts Sector Perform
Sep-29-17Reiterated Barclays Equal Weight $22 → $15
Aug-23-17Initiated William Blair Mkt Perform
Mar-16-17Reiterated RBC Capital Mkts Sector Perform $13 → $10
Mar-03-17Downgrade Barclays Overweight → Equal Weight $20 → $13
Nov-14-16Upgrade Credit Suisse Neutral → Outperform
Nov-11-16Upgrade Citigroup Neutral → Buy
Nov-11-16Reiterated RBC Capital Mkts Sector Perform $5 → $13
Jul-26-16Reiterated Wedbush Neutral $12 → $10
Jul-26-16Downgrade Credit Suisse Outperform → Neutral
Mar-01-16Reiterated RBC Capital Mkts Sector Perform $11 → $9
Mar-01-16Reiterated Barclays Overweight $100 → $40
Mar-01-16Downgrade Wedbush Outperform → Neutral $27 → $11
Aug-15-18 08:00AM  Today's Research Reports on Trending Tickers: Spark Therapeutics and PTC Therapeutics ACCESSWIRE
Aug-10-18 04:30PM  PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Aug-09-18 01:29PM  Ionis Pharmaceuticals (IONS) Q2 2018 Earnings Conference Call Transcript Motley Fool +5.84%
Aug-07-18 05:55PM  PTC Therapeutics (PTCT) Reports Q2 Loss, Misses Revenue Estimates Zacks
04:52PM  PTC Therapeutics: 2Q Earnings Snapshot Associated Press
04:01PM  PTC Therapeutics Reports Second Quarter 2018 Financial Results and Provides a Corporate Update PR Newswire
02:30PM  PTC Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-02-18 08:00AM  Akcea Therapeutics and PTC Therapeutics Collaborate to Commercialize Two Rare Disease Drugs in Latin America PR Newswire
Jul-26-18 08:00AM  PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2018 Financial Results PR Newswire
Jul-24-18 08:00AM  PTC Therapeutics Announces Publication of Data Demonstrating the Clinical Differentiated Benefit of Deflazacort PR Newswire
Jul-23-18 08:49AM  PTC Therapeutics (PTCT) Soars: Stock Adds 9.4% in Session Zacks
Jul-20-18 04:13PM  What's Behind PTC Therapeutics' 10% Rally Today Motley Fool +9.38%
08:10AM  Today's Research Reports on Trending Tickers: PTC Therapeutics and Seattle Genetics ACCESSWIRE
07:53AM  Benzinga's Daily Biotech Pulse: PTC To Buy Agilis, Zynerba To Offer Shares, Intuitive Surgical's Strong Q2 Benzinga
07:20AM  Free Technical Research on Riot Blockchain and Three More Biotech Equities ACCESSWIRE
Jul-19-18 04:46PM  PTC Therapeutics stock spikes on $200 million acquisition of Agilis Biotherapeutics MarketWatch
04:10PM  PTC Therapeutics to Acquire Agilis Biotherapeutics PR Newswire
08:39AM  Options Traders Expect Huge Moves in PTC Therapeutics (PTCT) Stock Zacks
Jul-09-18 08:00AM  PTC Therapeutics Announces Positive Data from its Translarna Phase II Clinical Trial in Children as Young as Two Years with Nonsense Mutation Duchenne Muscular Dystrophy PR Newswire
Jun-26-18 07:55AM  Recent Analysis Shows Church & Dwight Co., Innoviva, PTC Therapeutics, KBR, Murphy Oil, and F.N.B. Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Jun-25-18 02:21PM  Sarepta Therapeutics Could Be Onto Something Big Motley Fool -6.19%
01:47PM  Is PTC Therapeutics Stock a Buy? Motley Fool
Jun-22-18 09:52AM  Pharma Stock Roundup: PTCT Unveils Promising Data, RHHBY to Acquire Rest of FMI Zacks
09:20AM  Big Biotech Stock Pops and Drops This Week Motley Fool
Jun-21-18 08:44AM  PTC Therapeutics (PTCT) Jumps: Stock Rises 7.2% Zacks
Jun-20-18 03:35PM  Why Biogen, Ionis Could Be In Trouble As Others Move Into SMA Drugs Investor's Business Daily +7.22%
03:23PM  Sarepta Shares Keep Climbing and PTC Therapeutics Bounces Back TheStreet.com
08:00AM  Don't Get Too Excited About PTC Therapeutics (Yet) Motley Fool
07:45AM  Sarepta's Stock Soars on Encouraging Gene Therapy Results Zacks
Jun-19-18 06:10PM  Why PTC Therapeutics Dropped 30.6% Today After Jumping 27.5% Yesterday Motley Fool -30.58%
04:18PM  Biotech Firm Sarepta Surges 40% on Positive Test Results TheStreet.com
10:16AM  PTC Therapeutics' Spinal Muscular Atrophy Study Successful Zacks
08:10AM  Todays Research Reports on Stocks to Watch: PTC Therapeutics and Catalyst Biosciences ACCESSWIRE
Jun-18-18 09:09PM  PTC Therapeutics Inc (NASDAQ:PTCT) Is Expected To Breakeven Simply Wall St. +27.51%
04:31PM  Why Rent-A-Center, PTC Therapeutics, and Dropbox Jumped Today Motley Fool
01:15PM  Here's Why PTC Therapeutics Is Soaring While Biogen and Ionis Struggle Motley Fool
12:48PM  William Blair Upgrades PTC Therapeutics On Risdiplam Prospects Benzinga
12:33PM  Biogen plunges after rival drug for spinal muscular atrophy shows promise CNBC
11:03AM  PTC Therapeutics Up Most Since 2016 on Rare-Disease Drug Results Bloomberg
10:11AM  Roche SMA drug shines in study as costly new therapies advance Reuters
09:26AM  PTC Shares Skyrocket on Positive Data for Spinal Muscular Atrophy Drug TheStreet.com
09:11AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
08:45AM  Implied Volatility Surging for PTC Therapeutics (PTCT) Stock Options Zacks
Jun-16-18 01:36PM  Updated Preliminary Data from SMA FIREFISH Program in Type 1 Babies Presented at the CureSMA Conference PR Newswire
Jun-08-18 04:30PM  PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Jun-07-18 06:07PM  Edited Transcript of PTCT earnings conference call or presentation 9-May-18 8:30pm GMT Thomson Reuters StreetEvents
Jun-04-18 07:20AM  Initiating Free Research Reports on Pulmatrix and Three Other Biotech Equities ACCESSWIRE
Jun-01-18 07:45AM  CHMP Adopts Positive Opinion for the Expansion of the Translarna (ataluren) Label to Include Patients as Young as 2 Years of Age PR Newswire +6.52%
May-18-18 04:00PM  Notice to Current PTC Stockholders: Rosen Law Firm Announces Preliminary Approval of Derivative Settlement on Behalf of PTC Therapeutics, Inc. Business Wire
12:08PM  Small Caps And Blue Chips Lead; Stocks Attempt Breakouts Investor's Business Daily
May-09-18 04:46PM  PTC Therapeutics: 1Q Earnings Snapshot Associated Press
04:01PM  PTC Therapeutics Reports First Quarter 2018 Financial Results and Provides a Corporate Update PR Newswire
07:30AM  Analysis: Positioning to Benefit within Entergy, Schneider National, C.H. Robinson Worldwide, PTC Therapeutics, Guess?, and Immunomedics  Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
May-01-18 08:00AM  PTC Therapeutics to Host Conference Call to Discuss First Quarter 2018 Financial Results PR Newswire +5.27%
Apr-30-18 08:30AM  PTC Therapeutics to Participate at Upcoming Investor Conference PR Newswire
Apr-27-18 04:30PM  PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Apr-24-18 08:54PM  Preliminary Clinical Data from FIREFISH Trial in Type 1 SMA Patients Presented at the American Academy of Neurology Annual Meeting PR Newswire
Apr-12-18 04:30PM  PTC Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire
Apr-09-18 08:00AM  PTC Therapeutics Announces R&D Day to Review Multiple Orphan Disorder Programs PR Newswire
Apr-04-18 08:00AM  PTC Therapeutics and CHDI Foundation Announce a Collaboration on a Small-Molecule Therapeutic for Huntington's Disease PR Newswire
Mar-28-18 07:15PM  PTC Therapeutics Announces Pricing of Public Offering of Common Stock PR Newswire -15.29%
Mar-27-18 04:04PM  PTC Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire
Mar-22-18 08:54AM  3 Reasons Momentum Stock Investors Will Love PTC Therapeutics (PTCT) Zacks
Mar-19-18 04:30PM  PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Mar-15-18 08:00AM  FIREFISH Transitions into Pivotal Phase PR Newswire
Mar-07-18 08:26PM  Edited Transcript of PTCT earnings conference call or presentation 6-Mar-18 9:30pm GMT Thomson Reuters StreetEvents +9.28%
08:25AM  Investor Expectations to Drive Momentum within AVEO Pharmaceuticals, PTC Therapeutics, NGL Energy Partners LP, Bemis, CorMedix, and Patterson Companies Discovering Underlying Factors of Influence GlobeNewswire
Mar-06-18 04:21PM  PTC Therapeutics posts 4Q profit Associated Press
04:01PM  PTC Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update PR Newswire
12:15PM  PTC Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
08:05AM  PTC Therapeutics Q4 Earnings Preview Benzinga
Mar-01-18 12:16PM  [$$] Big Biotech Buys: Vericel, Achillion, PTC, Dicerna Barrons.com
08:00AM  PTC Therapeutics To Participate At Upcoming Investor Conferences PR Newswire
Feb-28-18 04:30PM  PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Feb-21-18 08:00AM  PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year End 2017 Financial Results PR Newswire
Feb-20-18 08:00AM  PTC Therapeutics Receives Formal Dispute Resolution Request Decision from the FDA's Office of New Drugs PR Newswire
Feb-13-18 08:00AM  PTC Therapeutics Launches Fourth Annual STRIVE Grant Award Program for Duchenne Muscular Dystrophy PR Newswire
Feb-09-18 08:00AM  PTC Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference PR Newswire
Jan-27-18 06:17AM  Preliminary Data from FIREFISH trial in Type 1 SMA Infants Presented at the International Scientific Congress on Spinal Muscular Atrophy PR Newswire
Jan-23-18 04:30PM  Data from RG7916 Programs in SMA to be Presented at the International Scientific Congress on Spinal Muscular Atrophy PR Newswire
Jan-19-18 12:06AM  Drugmaker Raises U.S. Price of Muscular-Dystrophy Treatment The Wall Street Journal
Jan-18-18 12:14PM  Drugmaker Raises U.S. Price of Muscular-Dystrophy Treatment The Wall Street Journal
Jan-09-18 08:43AM  PTC Therapeutics (PTCT) Jumps: Stock Rises 12.9% Zacks
03:00AM  PTC Therapeutics Clears Key Benchmark, Hitting 80-Plus RS Rating Investor's Business Daily
Jan-08-18 08:00AM  PTC Therapeutics Provides Corporate Update and Outlines 2018 Strategic Priorities PR Newswire +12.88%
Jan-05-18 04:30PM  PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Jan-03-18 08:00AM  PTC Therapeutics to Present at the 36th Annual JP Morgan Healthcare Conference PR Newswire
03:00AM  PTC Therapeutics Shows Market Leadership With Jump To 84 RS Rating Investor's Business Daily
Dec-29-17 06:25AM  How Does PTC Therapeutics Incs (NASDAQ:PTCT) Earnings Growth Stack Up Against Industry Performance? Simply Wall St.
Dec-26-17 01:06PM  PTC Therapeutics, Inc. Value Analysis (NASDAQ:PTCT) : December 26, 2017 Capital Cube
03:00AM  PTC Therapeutics Clears Key Benchmark, Hitting 80-Plus RS Rating Investor's Business Daily
Dec-25-17 07:16AM  PTC Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : PTCT-US : December 25, 2017 Capital Cube
Dec-15-17 04:30PM  PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
03:00AM  Stocks With Rising Relative Strength: PTC Therapeutics Investor's Business Daily
Dec-12-17 09:40AM  Update in Lawsuit for Investors in NASDAQ:PTCT shares against PTC Therapeutics, Inc. announced by Shareholders Foundation GlobeNewswire
Nov-29-17 12:08PM  ETFs with exposure to PTC Therapeutics, Inc. : November 29, 2017 Capital Cube
Nov-20-17 04:30PM  PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Nov-09-17 07:40AM  New Research: Key Drivers of Growth for Masco, Dextera Surgical, PTC Therapeutics, American International Group, Wyndham Worldwide, and Hecla Mining - A Look Behind the Scenes at Consolidated Results, Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Nov-08-17 06:29PM  ETFs with exposure to PTC Therapeutics, Inc. : November 8, 2017 Capital Cube
Nov-07-17 08:09AM  PTC Therapeutics, Inc. :PTCT-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017 Capital Cube
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and Emflaza (deflazacort) for treating Duchenne muscular dystrophy. It is developing Translarna, which is in Phase II clinical study for the treatment of nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5; and RG7916 for the treatment of patients with spinal muscular atrophy, as well as PTC596, an orally bioavailable and potent small molecule that has completed Phase I study, which targets solid tumor cell populations by reducing the activity and amount of BMI1. The company has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and research collaboration with CHDI Foundation, Inc. to discover and develop small-molecule therapeutics for Huntington's disease. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Almstead Neil GregoryEVP Research Pharma Ops & TechJun 19Option Exercise10.8520,000217,00037,154Jun 21 04:33 PM
Almstead Neil GregoryEVP Research Pharma Ops & TechJun 19Sale48.3120,000966,24017,154Jun 21 04:33 PM
Souza MarcioChief Operating OfficerJun 01Sale34.655,161178,82963,071Jun 04 04:22 PM
Almstead Neil GregoryEVP Research Pharma Ops & TechJan 05Sale18.03821,4785,125Jan 09 05:59 PM
Almstead Neil GregoryEVP Research Pharma Ops & TechJan 05Sale18.0362111,19717,154Jan 09 05:59 PM
Peltz Stuart WalterChief Executive OfficerJan 05Sale18.032,23040,20726,646Jan 09 05:59 PM
Almstead Neil GregoryEVP Research Pharma Ops & TechJan 04Sale17.67771,3615,207Jan 05 04:09 PM
Utter Christine MariePrincipal Financial OfficerJan 04Sale17.674127,2806,660Jan 05 04:07 PM